- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01577979
Adolescent Vaccination in the Medical Home: Established and Innovative Strategies
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Specific Aim 1: Within different types of primary care practices (pediatric practices in public, private, and managed care settings) serving adolescent patients of diverse socioeconomic and racial/ethnic backgrounds, to assess provider and staff attitudes regarding the desirability, feasibility, and potential sustainability of evidence-based and innovative strategies to promote adolescent vaccination in primary care practices.
Specific Aim 2: Among parents of adolescents (and/or adolescent patients) seen at primary care practices, to assess knowledge of existing national and state programs to promote vaccination, and to assess attitudes regarding, perceived barriers to, and acceptability of various practice-based strategies to promote adolescent vaccination.
Specific Aim 3: To implement and evaluate the effectiveness of a multi-faceted quality improvement program to promote adolescent vaccination within the medical home.
- Based upon findings from Specific Aims 1 and 2, develop a quality improvement program containing two or more interventions to promote adolescent vaccination.
- Select intervention patients to receive a multi-faceted vaccination quality improvement program and usual care patients which will continue receiving usual care.
- Compare the following primary outcome measure between intervention and usual care patients, overall and stratified by the type of practice setting: 1)percent of adolescents who received ≥ 1 or more needed vaccines or well-care visits
- Compare the following secondary outcome measures between intervention and usual care patients, overall and stratified by practice setting: 1) percent of adolescent patients with ≥ 1 Tdap vaccine; 2) percent of adolescent patients with ≥ 1 meningococcal (MCV4) vaccine; 3) percent of adolescent patients with ≥ 1 HPV vaccine; 4) percent of adolescent patients with ≥ 3 HPV vaccines; 5) percent of adolescent patients receiving ≥ 1 influenza vaccine during the preceding influenza season; 6) percent of adolescent patients with either a documented history of varicella disease or ≥ 2 varicella vaccines; 7) percent of adolescent patients with ≥ 2 MMR vaccines; 8) percent of adolescent patients with ≥ 3 hepatitis B vaccines; 9) percent of adolescent patients with ≥ 3 poliovirus vaccines; and 10) percent of adolescent patients with ≥ 1 missed vaccination opportunity, defined as having a patient visit to a primary care practice, being eligible for vaccination, and not receiving needed vaccines.
Specific Aim 3 (Kaiser Only): Design, implement and evaluate an HPV reminder/recall intervention based on obtaining the parents' and adolescents' preferences for reminder method and recipient at the time of the first dose of HPV.
- Compare 2nd and 3rd dose HPV vaccination rates among adolescents age 11-17 between intervention and usual care patients.
- Assess process measures related to feasibility and fidelity of implementation
Specific Aim 4: Evaluate the effect of a multi-faceted vaccination quality improvement program on the receipt of non-vaccination clinical preventive services recommended for adolescents.
a) Compare the following outcome measures between intervention and usual care patients, overall and stratified by the type of practice setting: 1) receipt of ≥ 1 health maintenance visits within a 12 month interval; 2) receipt of blood pressure screening; and 3) growth assessment, as documented by the measurement of weight and height and calculation of body mass index at a clinic visit.
Specific Aim 5: Assess the cost to participating practices of implementing a multi-faceted vaccination quality improvement program designed to promote adolescent vaccination.
Specific Aim 6: After conducting a multi-faceted quality improvement program to promote adolescent vaccination, to assess provider and staff attitudes about the program, in particular the perceived benefits of the program and factors which may facilitate or hamper the sustainability of the program within study practices.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Denver
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 11-17 years old
- Active patient (visit in last 2 years) of clinics in study
- Need one or more vaccines or well-care visit
Exclusion Criteria:
- Up to date on vaccines and well-care
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Reminder/Recall Strategy
The experimental group will consist of patients randomly selected from participating clinics.
Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging.
Text messages will be used to notify parents that their child is due for an immunization or well-care visit.
Parents will be able to reply with one of three response options.
Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method.
The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
|
Adolescents will be randomly selected from the participating private practices and safety net organization clinics.
Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit.
The text message will provide response instructions.
The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders.
Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit.
Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
Inne nazwy:
Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization.
The preference options include phone call, text message, or email.
The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders.
The clinics' usual method of reminder will be used for all other parents.
|
Brak interwencji: Usual Care
The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percent of adolescents who received ≥ 1 or more needed vaccines or well-care visits
Ramy czasowe: 6 months
|
Percent of adolescents who received ANY needed vaccine or well-care visit
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Percent of adolescent patients with 1 or more Tdap vaccine
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 1 or more meningococcal (MCV4) vaccine
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 1 or more HPV vaccine
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 3 or more HPV vaccines
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients receiving 1 or more influenza vaccine during the preceding influenza season
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with either a documented history of varicella disease or 2 or more varicella vaccines
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 2 or more MMR vaccines
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 3 or more hepatitis B vaccines
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 3 or more poliovirus vaccines
Ramy czasowe: 6 months
|
6 months
|
Percent of adolescent patients with 1 or more missed vaccination opportunity, defined as having a patient visit to a primary care practice, being eligible for vaccination, and not receiving needed vaccines
Ramy czasowe: 6 months
|
6 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Allison Kempe, MD, MPH, University of Colorado Denver, The Children's Hospital of Colorado
Publikacje i pomocne linki
Publikacje ogólne
- Kempe A, O'Leary ST, Shoup JA, Stokley S, Lockhart S, Furniss A, Dickinson LM, Barnard J, Daley MF. Parental Choice of Recall Method for HPV Vaccination: A Pragmatic Trial. Pediatrics. 2016 Mar;137(3):e20152857. doi: 10.1542/peds.2015-2857. Epub 2016 Feb 26.
- O'Leary ST, Lee M, Lockhart S, Eisert S, Furniss A, Barnard J, Eblovi DE, Shmueli D, Stokley S, Dickinson LM, Kempe A. Effectiveness and Cost of Bidirectional Text Messaging for Adolescent Vaccines and Well Care. Pediatrics. 2015 Nov;136(5):e1220-7. doi: 10.1542/peds.2015-1089. Epub 2015 Oct 5. Erratum In: Pediatrics. 2016 Sep;138(3):null.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 10-1209
- U01IP000310 (Grant/umowa NIH USA)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .